Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Radical -xh acid – or anhydride – acid halide or salt thereof...
Reexamination Certificate
2002-01-03
2004-02-24
Weddington, Kevin E. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Radical -xh acid, or anhydride, acid halide or salt thereof...
Reexamination Certificate
active
06696492
ABSTRACT:
The invention described herein relates to the use of L-carnitine and its alkanoyl derivatives, optionally in the form of a pharmaceutically acceptable salt, for the preparation of a medicament which is useful for the treatment of patients suffering from diabetic and/or dysmetabolic nephropathy.
BACKGROUND OF THE INVENTION
Nephropathy caused by glomerular damage not strictly related to an immunological cause (autoimmune disease) or to glomerulonephritis is today one of the most frequent causes of chronic kidney failure and subsequent terminal uraemia. In Western society, 30-35% of patients undergoing dialysis have had a diagnosis of nephropathy due to dysmetabolism which has reduced and eventually abolished their renal function.
The first signs of such disease are manifested a number of years after the onset of diabetes mellitus and/or hyperlipidaemia and consist in the presence of microalbuminuria (presence of abnormal excretion of albumin quantified in amounts ranging from 30 to 300 mg in 24-hour urine samples), which is an unmistakable sign of damage at the level of the renal glomerular filtration barrier.
The earliest morphological abnormalities of the nephropathy consist in a thinning of the glomerular basal membrane and an increase in the mesangial component due to an accumulation of extracellular matrix. This accumulation of glomerular matrix is the main cause of a reduced nutrient and oxygen supply capacity at the level of the glomerular wall and, as a final event, leads to glomerulosclerosis and the loss of filtering capacity on the part of the glomerule. The residual glomerules adapt to the need to purify and regulate the reabsorption of liquids and salts via a glomerular hyperfiltration and hypertension mechanism, not so much directly associated with an actual state of systemic arterial hypertension, but denoting rather an organ disease. This adaptation, however, leads to an increase in glomerulosclerosis and to a subsequent further reduction in the residual function of the glomerules. At this stage, the arteriolar hypertension at precapillary level is a stimulus for enhancing the glomerulosclerosis. The renal vascular system shows typical signs of widespread atherosclerosis, often complicated by the presence of a frank associated lipidaemia. In fact, non-enzymatic glycosylation of lipoproteins may speed up the atherosclerotic phenomenon. The presence of HDL and antioxidant substances in these conditions may exert an antiatherogenic action. In conditions of hyperglycaemia there is also increased secretion of endothelin-1 as well as a reduction of nitrous oxide release by the endothelium.
The aim of the therapy currently available is to delay the progression of the nephropathy by means of dietetic and pharmacological control of the hyperglycaemia and/or dyslipidaemia, sometimes in combination with the use of calcium antagonists and/or ACE inhibitors which are useful for reducing systemic and glomerular blood pressure. Despite all the therapeutic measures currently available, the present expectancy for maintaining minimal renal functional capability is not more than 5 to 10 years. The patients suffering from this condition are in any event destined to develop terminal chronic kidney failure in this time period, requiring dialysis-type replacement treatment or a kidney transplant.
It is clear that the present situation entails progressive deterioration of the quality of life of the patient, whose prospects of entering into dialysis treatment or, even worse, of facing a kidney transplant, with all the attendant problems of having to wait for an available organ, and, in any case, the prospect of having to undergo complex transplant surgery, with its known consequences, make it highly desirable to find a solution which the present state of the art is unable to offer. In particular, a medicament capable at least of delaying, if not of resolving, the condition of terminal uraemia of patients suffering from chronic kidney failure is highly desirable.
Propionyl L-carnitine is known to exert a protective action on the endothelial cells and, in previous organ ischaemia and reperfusion experiments, has been found to be capable of reducing the damage induced by the ischaemia (Di Silverio et al., Acta Urol. Ital., 1993, (I), 71-75). This latter study, however, only shows the ability of propionyl L-carnitine to reduce acute postoperative ischaemic damage in patients with kidney stones and chronic kidney failure.
Propionyl L-carnitine is also capable of improving the oxidative metabolism of myocardial and skeletal muscle cells subjected to a reduced blood supply.
It has also been recently demonstrated in studies conducted in animals that the administration of propionyl L-carnitine is capable of improving the functional capability and perfusion of the peripheral nerves in rats in which a diabetic state was induced by the administration of streptozocin (Hotta et al., The Journal of Pharmacology and Experimental Therapeutics, 276:49-55, 1996).
Moreover, again in rats in which a diabetic state was induced by the administration of streptozocin, it has been demonstrated that the high plasma lipid levels (total cholesterol, triglycerides, LDL) as a result of the lipid dysmetabolism induced by the diabetic state are reduced by treatment with propionyl L-carnitine.
It has now surprisingly been found that L-carnitine and its lower alkanoyl derivatives have a thoroughly unexpected action in terms of functional recovery in patients suffering from chronic diabetic and/or dysmetabolic nephropathy.
ABSTRACT OF THE INVENTION
One subject of the invention described herein is the use of L-carnitine and its lower alkanoyl derivatives, where what is meant by lower alkanoyl derivative is a straight or branched aliphatic acyl residue with from 2 to 8 carbon atoms, optionally in the form of a pharmaceutically acceptable salt for the preparation of a medicament useful for the treatment of patients suffering from diabetic and/or dysmetabolic nephropathy.
L-carnitine and its lower alkanoyl derivaties are well known for various therapeutic uses. In particular, U.S. Pat. No. 4,327,167, in the name of the applicant, describes the use of alkanoyl carnitines, as understood here above, in a therapeutic method for the treatment of chronic uraemic patients undergoing regular dialysis. Polysaline solutions for haemodialysis containing an alkanoyl carnitine have also been described. European patent EP 0793962, in the name of the applicant, describes the use of propionyl L-carnitine for the preparation of a medicament useful for the selective treatment of chronic obliterating atherosclerosis (intermittent claudication). Italian patent IT 1155772, taken out in the name of the applicant, describes the use of alkanoyl L-carnitine in the therapy of myocardial anoxia, ischaemia, arrhythmia syndromes and heart failure. U.S. Pat. 4,255,449, issued in the name of the applicant, described the use of L-carnitine in the treatment of dyslipidaemias. Patent application WO99/06039, filed in the name of the applicant, describes the use of L-carnitine and its alkanoyl derivatives in combination with polycosanols for the treatment of dyslipidaemias.
WO 98/01128 discloses the use of alkaanoyl L-carnitines for the therapeutic treatment of diseases related to IGF-1.
Among the pathologies mentioned in WO 98/01128 type-II diabetes or ischemic damage at the renal level are mentioned.
WO 98/33494 discloses compositions useful for the treatment and prevention of diabetic complications associated with microangiopathy, such as nephropathy.
WO 98/33494 discloses that decreased L-carnitine levels are common in insulin dependent diabetics and that carnitine supplementation reduces serum triglycerides.
In Infusionstherapie October 1991;18(5):224-6 is reported that the use of L-carnitine, in renally insufficient children, reduces the serum triglyceride levels and that L-carnitine is an antiatherogenic compound.
In the above cited publications there is no suggestion how to use L-carnitine or alkanoyl L-carnitines for treating diabetic and/or dysmetabol
Cavazza Claudio
Valentini Giovanni
Nixon & Vanderhye P.C.
Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.
Weddington Kevin E.
LandOfFree
Use of L carnitine and its alkanoyl dervatives for the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of L carnitine and its alkanoyl dervatives for the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of L carnitine and its alkanoyl dervatives for the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3302273